3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
13
Prostatic Neoplasms
9
Carcinoma, Hepatocellular
8
Liver Neoplasms
6
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Squamous Intraepithelial Lesions
2
Neoplasms
2
Lymphatic Metastasis
2
Locally Advanced Pancreatic Cancer
2
Kidney Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Interventions
Sorafenib
5
lenvatinib
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sintilimab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
pembrolizumab
1
ozanimod
1
linifanib
1
genexol-PM
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
camrelizumab
1
belinostat
1
bavituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liver Diseases
×
Electroporation
×
Clear all
NCT07191548
2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA
Not yet recruiting
50 enrolled